Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Core Viewpoint - Johnson & Johnson has entered a voluntary agreement with the Trump Administration aimed at improving access to medicines and reducing costs for American patients, while also receiving an exemption from tariffs for its pharmaceutical products [1][2]. Group 1: Investment and Manufacturing - The company is committed to a $55 billion investment in U.S. manufacturing, research and development, and technology by early 2029, with billions already initiated in the last 10 months [3][4]. - As part of this investment, Johnson & Johnson is establishing two new U.S. manufacturing facilities, including a cell therapy site in Pennsylvania and a drug product facility in North Carolina [4]. - A $2 billion biologics manufacturing facility is under construction in Wilson, North Carolina, expected to create approximately 5,000 skilled jobs [5]. - The company has secured a new 160,000+ square foot biopharmaceutical manufacturing site in Holly Springs, North Carolina, with a $2 billion commitment over the next 10 years, creating around 120 new jobs [6]. Group 2: Access and Pricing - Johnson & Johnson is participating in TrumpRx.gov, a platform that allows American patients to purchase medicines at significantly discounted rates [8]. - The company aims to enable American patients to access medicines at prices comparable to those in other developed countries and provide Medicaid program access at similar pricing [8].